泛素特异性蛋白酶4是非酒精性脂肪性肝病小鼠代谢功能障碍的内源性负调控因子
该研究探讨泛素特异性蛋白酶4(USP4)在非酒精性脂肪性肝病(NAFLD)中的作用。USP4在NAFLD患者肝脏、高脂饮食或ob/ob小鼠模型及棕榈酸处理的肝细胞中表达下调;肝细胞特异性敲除USP4加重高脂饮食诱导小鼠的肝脂肪变、胰岛素抵抗和炎症,而过表达USP4减轻两种NAFLD模型的病理改变。机制上USP4直接结合并去泛素化TAK1,抑制下游NF-κB和JNK级联激活,从而逆转IRS-AKT-GSK3β信号紊乱。
要点
- USP4在NAFLD患者肝脏及高脂饮食、ob/ob小鼠模型和棕榈酸处理肝细胞中表达显著下调。
- 肝细胞特异性敲除USP4加重高脂饮食小鼠肝脂肪变、胰岛素抵抗和炎症反应。
- 肝细胞过表达USP4通过去泛素化TAK1抑制NF-κB和JNK通路,减轻两种NAFLD模型病理改变。
核心结论
- USP4作为NAFLD及相关代谢紊乱的关键抑制因子发挥作用。
研究设计与样本
- 研究采用NAFLD患者肝脏样本、高脂饮食诱导和ob/ob基因缺陷NAFLD小鼠模型以及棕榈酸处理的肝细胞,结合肝细胞特异性USP4敲除与过表达实验。
主要发现
- USP4在NAFLD患者肝脏、高脂饮食或ob/ob小鼠模型肝脏及棕榈酸处理的肝细胞中表达显著下调。
- 肝细胞特异性敲除USP4加重高脂饮食诱导NAFLD小鼠的肝脂肪变、胰岛素抵抗和炎症反应。
- 肝细胞过表达USP4显著减轻两种不同NAFLD模型的病理改变。
- USP4直接结合并去泛素化TAK1,抑制下游NF-κB和JNK级联激活,逆转IRS-AKT-GSK3β信号紊乱。
- USP4与TAK1的相互作用及随后的TAK1去泛素化是改善代谢功能障碍所必需的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis (HS), insulin resistance (IR), and inflammation, poses a high risk of cardiometabolic disorders. Ubiquitin specific protease 4 (USP4), a deubiquitinating enzyme, is pivotally involved in regulating multiple inflammatory pathways; however, the role of USP4 in NAFLD is unknown. Here, we report that USP4 expression was dramatically down-regulated in livers from NAFLD patients and different NAFLD mouse models induced by high-fat diet (HFD) or genetic deficiency (ob/ob) as well as in palmitate-treated hepatocytes. Hepatocyte-specific USP4 depletion exacerbated HS, IR, and inflammatory response in HFD-induced NAFLD mice. Conversely, hepatic USP4 overexpression notably alleviated the pathological alterations in two different NAFLD models. Mechanistically, hepatocyte USP4 directly bound to and deubiquitinated transforming growth factor-β activated kinase 1 (TAK1), leading to a suppression of the activation of downstream nuclear factor kappa B (NF-κB) and c-Jun N-terminal kinase (JNK) cascades, which, in turn, reversed the disruption of insulin receptor substrate/protein kinase B/glycogen synthase kinase 3 beta (IRS-AKT-GSK3β) signaling. In addition, USP4-TAK1 interaction and subsequent TAK1 deubiquitination were required for amelioration of metabolic dysfunctions. Conclusion: Collectively, the present study provides evidence that USP4 functions as a pivotal suppressor in NAFLD and related metabolic disorders. (Hepatology 2018; 00:000-000).
引用
- Zhao Y, Wang F, Gao L, et al. Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Metabolic Dysfunctions in Nonalcoholic Fatty Liver Disease in Mice. Hepatology. 2018. PMID: 29573006. doi:10.1002/hep.29889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。